Physician profile
Adam J Smith
NPI 1962734368
$296,148.08
in general payments reported to CMS, 2019-2025
26 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $35K · 2021: $28K · 2022: $24K · 2023: $28K · 2024: $43K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $29K · Travel and Lodging: $11K · Food and Beverage: $6,867 · Honoraria: $4,800 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,342.80 |
| Consulting Fee | $28,532.50 |
| Travel and Lodging | $10,593.88 |
| Food and Beverage | $6,867.03 |
| Honoraria | $4,800.00 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $119,815.29 | 2019-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $73,141.95 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,822.74 | 2019-2025 | Spiriva Respimat, Jascayd, Ofev |
| Regeneron Healthcare Solutions, INC. | $24,739.70 | 2019-2025 | Dupixent |
| Insmed, INC. | $14,730.33 | 2023-2025 | Arikayce |
| Regeneron Pharmaceuticals, INC. | $6,538.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $5,706.83 | 2019 | |
| Verona Pharma, INC. | $5,124.17 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $3,768.97 | 2019-2024 | Yupelri |
| Noah Medical Corporation | $3,260.77 | 2023 | |
| Roche Products Limited | $2,751.21 | 2019 | |
| Gyrus Acmi, INC. | $2,236.50 | 2024-2025 | Medical Control Unit For Endosurgery Uces-4 |
| Radiometer America, INC | $1,950.00 | 2022 | |
| Becton, Dickinson and Company | $850.00 | 2022 | |
| Amgen INC. | $766.67 | 2022-2025 | Tezspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu A/S | $750.00 | 2024 | |
| Baxter Healthcare | $300.00 | 2019 | |
| United Therapeutics Corporation | $202.20 | 2020-2024 | Tyvaso |
| Genzyme Corporation | $191.65 | 2019-2024 | |
| Philips North America LLC | $183.66 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Galvanize Therapeutics, INC | $79.48 | 2024 | Aliya System |
| Genentech USA, INC. | $68.61 | 2019-2021 | |
| Astellas Pharma US INC | $51.24 | 2025 | Veozah |
| Tactile Systems Technology INC | $50.00 | 2020 | |
| Sunovion Pharmaceuticals INC. | $46.46 | 2019 | |
| Pfizer INC. | $21.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.